Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

202d91a3263ce892b649887d0.uHMSNsZZ4SSC9vgUCF7Jg4ULem5DGoIvdfK0PbraWMo.lQlAT4kph0ywv40gOzOlx9xtED0xT_AWB7j5cenuYJ7qAWRFlwrZbeublw~4232f2a21b852322e7916b6dc5f23c64
07-08 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says MT
07-08 Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating MT
07-07 Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 MT
07-07 RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating MT
07-06 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow… Zonebourse
07-06 HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133 MT
06-08 Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says MT
05-20 Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165 MT
05-19 Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating MT
05-11 Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says MT
05-11 Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170 MT
05-08 Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148 MT
05-08 Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says MT
05-08 Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175 MT
04-28 Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating MT
04-17 Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating MT
04-17 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating MT
04-13 Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating MT
04-10 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating MT
04-08 Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says MT
04-07 RBC Adjusts Price Target on Gilead Sciences to $123 From $118, Maintains Sector Perform Rating MT
03-31 Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says MT
02-25 Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating MT
02-25 Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… Zonebourse
02-24 Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-0.59%
-3.47%
+1.44%
+5.81%
+12.99%
-2.1%
-3.22%
-3.57%
+20.49%
Average +3.09%
Weighted average by Cap. +1.20%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
135.82USD
Average target price
158.30USD
Spread / Average Target
+16.55%
High Price Target
180.00USD
Spread / Highest target
+32.53%
Low Price Target
120.00USD
Spread / Lowest Target
-11.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
Truist Securities
RBC Capital Markets
HSBC
Maxim
Daiwa Securities
Rothschild & Co Redburn
Leerink Partners
Goldman Sachs
Cantor Fitzgerald
Citigroup
Barclays
Argus
Mizuho Securities
Wolfe Research
TD Cowen
Deutsche Bank Securities
Baird
Scotiabank
Bernstein
BMO Capital
Needham & Co.
Oppenheimer
JPMorgan Chase
Wells Fargo Securities
UBS
DBS Bank
BofA Securities
Jefferies & Co.
Redburn Atlantic
Piper Sandler
Raymond James
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Redburn
DZ BANK Elmar Kraus
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
135.82USD
Average target price
158.30USD
Spread / Average Target
+16.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. GIS Stock
  5. Consensus Gilead Sciences, Inc.